Eton Pharmaceuticals Issues Amended Financial Report on Acquired Increlex Product
Eton Pharmaceuticals Inc. has amended its Form 8-K to include audited and unaudited financial statements for its acquired INCRELEX® product, covering 2023 and 2022, and the nine months ending September 30, 2024 and 2023. The amendment, filed for SEC compliance, includes a report from independent accountants but is not a complete financial presentation. The original content was published via the SEC's EDGAR system on November 18, 2025.
Eton Pharmaceuticals Inc. has filed an amendment to its Form 8-K, providing audited and unaudited abbreviated financial statements related to its acquired INCRELEX® product for the years ended December 31, 2023 and 2022, and for the nine months ended September 30, 2024 and 2023. The amendment includes a report from independent certified public accountants and notes that the financial statements are prepared specifically for SEC compliance and are not a complete presentation of the product line’s financials. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eton Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-035597), on November 18, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
